EyePoint Pharmaceuticals Inc
EYPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.14B
Close$
$-1.90
115.4% downside
Current Fair Value
115.4% downsideOvervalued by 115.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.14 Billion |
|---|---|
| Enterprise Value | $1.08 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.17 |
| Beta | 1.77 |
| Outstanding Shares | 85,999,000 |
Return
| Return on Equity | -117.84% |
|---|---|
| Return on Assets | -94.23% |
| Return on Invested Capital | -111.23% |
Valuation & Multiples
| P/E Ratio | -4.3 |
|---|---|
| PEG | -4.9 |
| Price to Sales | - |
| Price to Book Ratio | 6.17 |
| Enterprise Value to Revenue | 141.97 |
| Enterprise Value to EBIT | -3.88 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$352,833
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.94
Average shareholder expectationRevenue Estimate
$383,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3501▲ 5.22% |
|---|---|
| Total Calls | 1,646,169▲ 138.92% |
| Total Puts | 576,400▲ 180.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.75%▼ 12.19% |
|---|---|
| Total Invested | $1.14B▼ 25.18% |
| Investors Holding | 202▲ 28.00% |
ESG Score
No data